All these results suggest that ESR1 mutations are rare in newly diagnosed, untreated breast cancers but appear to be frequently acquired during progression to hormone resistance, especially in the context of estrogen deprivation therapy. This evidence concerns the gene ESR1 and breast carcinoma.